FUSN vs. INBX, BEAM, DNA, ADMA, RXRX, NMRA, TARS, SANA, APGE, and FDMT
Should you be buying Fusion Pharmaceuticals stock or one of its competitors? The main competitors of Fusion Pharmaceuticals include Inhibrx (INBX), Beam Therapeutics (BEAM), Ginkgo Bioworks (DNA), ADMA Biologics (ADMA), Recursion Pharmaceuticals (RXRX), Neumora Therapeutics (NMRA), Tarsus Pharmaceuticals (TARS), Sana Biotechnology (SANA), Apogee Therapeutics (APGE), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "biological products, except diagnostic" industry.
Fusion Pharmaceuticals (NASDAQ:FUSN) and Inhibrx (NASDAQ:INBX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations, community ranking and media sentiment.
Fusion Pharmaceuticals has higher revenue and earnings than Inhibrx. Fusion Pharmaceuticals is trading at a lower price-to-earnings ratio than Inhibrx, indicating that it is currently the more affordable of the two stocks.
Fusion Pharmaceuticals has a net margin of -4,136.55% compared to Inhibrx's net margin of -13,408.95%. Fusion Pharmaceuticals' return on equity of -46.59% beat Inhibrx's return on equity.
Fusion Pharmaceuticals received 10 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 64.06% of users gave Fusion Pharmaceuticals an outperform vote while only 60.78% of users gave Inhibrx an outperform vote.
72.9% of Fusion Pharmaceuticals shares are held by institutional investors. Comparatively, 82.5% of Inhibrx shares are held by institutional investors. 7.8% of Fusion Pharmaceuticals shares are held by company insiders. Comparatively, 25.8% of Inhibrx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Fusion Pharmaceuticals had 7 more articles in the media than Inhibrx. MarketBeat recorded 13 mentions for Fusion Pharmaceuticals and 6 mentions for Inhibrx. Inhibrx's average media sentiment score of 0.54 beat Fusion Pharmaceuticals' score of -0.06 indicating that Inhibrx is being referred to more favorably in the news media.
Fusion Pharmaceuticals presently has a consensus target price of $20.25, indicating a potential downside of 5.73%. Inhibrx has a consensus target price of $27.00, indicating a potential downside of 21.26%. Given Fusion Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Fusion Pharmaceuticals is more favorable than Inhibrx.
Fusion Pharmaceuticals has a beta of -0.69, indicating that its share price is 169% less volatile than the S&P 500. Comparatively, Inhibrx has a beta of 2.87, indicating that its share price is 187% more volatile than the S&P 500.
Summary
Fusion Pharmaceuticals beats Inhibrx on 12 of the 18 factors compared between the two stocks.
Get Fusion Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FUSN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FUSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fusion Pharmaceuticals Competitors List
Related Companies and Tools
